Coronavirus disease 2019 (COVID-19) pandemic, central-line–associated bloodstream infection (CLABSI), and catheter-associated urinary tract infection (CAUTI): The urgent need to refocus on hardwiring prevention effortsOriginal Article Published on 2021-02-192022-10-30 Journal: Infection Control and Hospital Epidemiology [Category] COVID-19, MERS, [키워드] Admission affecting bloodstream bloodstream infection Candida Care change coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 pandemic COVID-19 patient effort evaluate event hospital hospitalizations hospitals increases in Infection maintain network NHSN pandemic Patient patient population performed Prevalence representing Retrospective study Safe Safety Staphylococcus urinary tract infection [DOI] 10.1017/ice.2021.70 PMC 바로가기 [Article Type] Original Article
Impact of coronavirus disease 2019 (COVID-19) on US Hospitals and Patients, April–July 2020코로나바이러스 질병 2019(COVID-19)가 미국 병원 및 환자에 미치는 영향, 2020년 4월–7월Original Article Published on 2021-02-192022-09-10 Journal: Infection Control and Hospital Epidemiology [Category] MERS, SARS, 치료기술, [키워드] center collected Control coronavirus coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 hospitalization Critical declined disease control estimate Guidance hospital Hospitalization hospitalizations hospitalized patient hospitalized patients Impact IMPROVE Inpatient Inpatients magnitude mechanical ventilators module multiple imputation National National Healthcare Safety Network network NHSN number of inpatients outcome Patient proportion public health Quantitative Region respiratory Respiratory Coronavirus Safety SARS-CoV-2 South Spread Surveillance the United State The United States time United States ventilator virus Weighting with COVID-19 [DOI] 10.1017/ice.2021.69 PMC 바로가기 [Article Type] Original Article
An Open Label Trial to Assess Safety of Losartan for Treating Worsening Respiratory Illness in COVID-19Medicine Published on 2021-02-172022-10-31 Journal: Frontiers in Medicine [Category] COVID-19, [키워드] 1:1 Administered adverse event adverse events age angiotensin receptor blocker angiotensin receptor inhibitors ARBs average Bayesian capillary leakage Comorbidities contributing to control group controls Coronavirus disease 2019 COVID-19 COVID−19 cumulative disease severity Efficacy Endpoint enrolled Enrollment hospital discharge Hospitalized illness IMPROVE incidence incidence rate inclusion criteria Inflammation lAbel losartan Lungs male measure open label oral outcome participant Patient Poisson regression post-hoc randomized trial renin-angiotensin system respiratory respiratory compromise Respiratory failure Safe Safety secondary Sex treating treatment group Trial vital status [DOI] 10.3389/fmed.2021.630209 PMC 바로가기 [Article Type] Medicine
Comparative risk of infections among real-world users of biologics for juvenile idiopathic arthritis: data from the German BIKER registryarticle Published on 2021-02-162024-09-02 Journal: Rheumatology International [Category] 대상포진, [키워드] biologics infections juvenile idiopathic arthritis Safety [DOI] 10.1007/s00296-020-04774-3 PMC 바로가기 [Article Type] article
Safety and Outcomes Associated with the Pharmacological Inhibition of the Kinin–Kallikrein System in Severe COVID-19중증 COVID-19에서 키닌-칼리크레인 시스템의 약리학적 억제와 관련된 안전성 및 결과Article Published on 2021-02-162022-09-10 Journal: Viruses [Category] 신약개발, [키워드] accumulation ACE2 angiotensin angiotensin converting enzyme 2 Angiotensin-converting enzyme angiotensin-converting enzyme 2 approved Autopsies Autopsy Blood bradykinin case control study catalytic activity Cell cells cellular changes in Clinical improvement Cohort component components Compound Computed tomography coronavirus coronavirus disease coronavirus disease 19 COVID-19 develop Dexamethasone diffusion disease disease severity edema enzyme eosinophils Evidence expressed Hypoxemia Icatibant Inflammation Inflammatory inhibition inhibitor interfere Kallikrein lung lung alveolar marker Mortality Patient pharmacological promoted receptor reduce mortality respiratory Safe Safety SARS-CoV-2 SARS-COV-2 infection severe cases severe COVID-19 severe respiratory syndrome shown System tested Treatment [DOI] 10.3390/v13020309 PMC 바로가기 [Article Type] Article
Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trialCOVID-19 환자에서 고용량 비타민 C의 안전성과 효과: 무작위 공개 임상 시험Randomized Controlled Trial Published on 2021-02-112022-08-13 Journal: European Journal of Medical Research [Category] 임상, 치료제, [키워드] 2019-nCoV added addition age and gender antioxidant body temperature boosting immunity clinical trial conducted control group Controlled trial COVID-19 COVID-19 disease COVID-19 infection discharge effective Effectiveness Efficacy function HDIVC High-dose high-dose intravenous vitamin C High-dose vitamin C Hospitalization Hydroxychloroquine ICU intensive care intensive care unit intravenous IRCT20200411047025N1 Laboratory results Lopinavir Lopinavir/ritonavir median Mortality no significant difference Open-label outcome oxygen oxygen saturation Patient patients peripheral Peripheral capillary oxygen saturations Pneumonia Randomized receiving regimen regimens Result Ritonavir Safety SARS-CoV-2 severe COVID-19 disease Severe COVID-19 Infection significantly significantly lower statistically significant difference treated treatment group treatment regimen Trial registration two group two groups underlying diseases Vitamin Vitamin C water-soluble nutrient [DOI] 10.1186/s40001-021-00490-1 PMC 바로가기 [Article Type] Randomized Controlled Trial
Safety and feasibility of using acellular sterile filtered amniotic fluid as a treatment for patients with COVID-19: protocol for a randomised, double-blinded, placebo-controlled clinical trialCOVID-19 환자를 위한 치료법으로 무균 무균 여과 양수 사용의 안전성 및 타당성: 무작위 배정, 이중 맹검, 위약 대조 임상 시험 프로토콜Article Published on 2021-02-112022-09-11 Journal: BMJ Open [Category] 임상, [키워드] administration amniotic Amniotic fluid approved Biomarker C-reactive protein cellular clinical trial clinical trials clinically collected conditions COVID-19 Critical Critical care determine double-blinded drug Drug administration Ethics experimental models FDA feasibility filtered food hospital Hospitalised patients Human include Inflammation Inflammatory Inflammatory response institutional review board Intensive intensive & intensive care intravenous laboratory-confirmed Laboratory-confirmed COVID-19 life methodology Mortality New outcome Patient patients with COVID-19 peer-reviewed pilot study Placebo placebo-controlled clinical trial Primary outcome protocol randomised recruited reduce Registered registration number respiratory respiratory medicine (see thoracic medicine) Result Safety secondary Secondary outcomes shown Therapeutic treatment Thoracic tissue tissue injury Treatment Trial university US FDA US Food and Drug Administration Utah ventilator-free day Ventilator-free days [DOI] 10.1136/bmjopen-2020-045162 PMC 바로가기 [Article Type] Article
A Virtual Ward Model of Care for Patients With COVID-19: Retrospective Single-Center Clinical StudyOriginal Paper Published on 2021-02-102022-10-30 Journal: Journal of Medical Internet Research [Category] COVID-19, MERS, [키워드] 95% CI Analysis arthralgia Care clinical clinical care cohort of patient COVID-19 cycle threshold death diagnostic discharged Efficacy Escalation evaluate Factor Health hospital Hospitalization hypertension illness onset implementation Innovation Isolation mechanical ventilation median Model Nasopharyngeal swab objective Odds ratio Patient patients patients with COVID-19 polymerase chain Remote care required Result Safe Safety sputum production supplemental oxygen Telemedicine treat treated variable virtual health care virtual ward ward was performed were recorded with COVID-19 [DOI] 10.2196/25518 PMC 바로가기 [Article Type] Original Paper
A Randomized, Double-Blind, Multicenter Clinical Study Comparing the Efficacy and Safety of a Drug Combination of Lopinavir/Ritonavir-Azithromycin, Lopinavir/Ritonavir-Doxycycline, and Azithromycin-Hydroxychloroquine for Patients Diagnosed with Mild to Moderate COVID-19 InfectionsResearch Article Published on 2021-02-092022-10-27 Journal: Biochemistry Research International [Category] COVID-19, [키워드] Administered administration ALT AST clinical clinical study clinical symptom Combination conducted Control COVID-19 COVID-19 vaccine creatinine CRP decrease demographic data diagnosed dose double-blind doxycycline drug drug combination effective Efficacy and safety elevated evaluate group Hydroxychloroquine IL-10 IL-6 IL-6 levels increase in Indonesia Infection infections material measure Mild Mild symptom moderate Moderate COVID-19 multicenter observation older patient Other overcome participated Patient PCR PCR swab produced Randomized reduced required Result RT-PCR test Safety Serum level setting significant decrease significantly significantly lower subject TNF- α treat treated Treatment treatment for COVID-19 treatment group virus load [DOI] 10.1155/2021/6685921 PMC 바로가기 [Article Type] Research Article
A preliminary report of a randomized controlled phase 2 trial of the safety and immunogenicity of mRNA-1273 SARS-CoV-2 vaccineClinical Trial Published on 2021-02-092023-06-16 Journal: Vaccine [Category] MERS, SARS, [키워드] AE, adverse event ARs, adverse reaction bAb, serum binding antibody CoV, coronaviruses COVID-19 COVID-19, Coronavirus disease 2019 CRO, clinical research organization eDiary, electronic diary ELISA, enzyme-linked immunosorbent assay immunogenicity LLOQ, lower limit of quantification MAAE, medically-attended adverse event MN, microneutralization mRNA-1273 mRNA, messenger Ribonucleic Acid nAb, serum neutralizing antibody Phase 2 RT-PCR, Reverse transcription polymerase chain reaction SAE, serious adverse event Safety SARS-CoV-2 SARS-CoV-2, Severe acute respiratory syndrome coronavirus 2 ULOQ, upper limit of quantification Vaccine [DOI] 10.1016/j.vaccine.2021.02.007 PMC 바로가기 [Article Type] Clinical Trial